CONMED (CNMD) vs Establishment Labs (ESTA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Establishment Labs (ESTA) has outperformed CONMED (CNMD) over the past year, gaining 53.7% versus a loss of 2.2%. Over five years, ESTA leads with a -19.9% price change compared with -68.7% for CNMD. Establishment Labs is the larger company by market cap ($1.84 billion vs $1.33 billion), about 1.4 times the size.
On valuation, CONMED trades at a lower forward P/E (9.3x vs 1027.8x for Establishment Labs). CONMED pays a dividend yielding 0.45%, while Establishment Labs does not currently pay one. CONMED converts more of its revenue into profit, with a net margin of 3.4% versus -24.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNMD | ESTA |
|---|---|---|
| Share price | $44.42 | $61.67 |
| Market cap | $1.33B | $1.84B |
| 1-day change | -1.53% | +1.75% |
| YTD return | +9.41% | -15.38% |
| 1-year return | -2.18% | +53.71% |
| 5-year return | -68.72% | -19.91% |
| P/E ratio (TTM) | 24.01 | — |
| Forward P/E | 9.29 | — |
| EPS (TTM) | $1.85 | $-1.30 |
| Dividend yield | 0.45% | 0.00% |
| Annual dividend | $0.20 | $0.00 |
| Revenue (latest FY) | $1.37B | $211.08M |
| Revenue growth (YoY) | +5.18% | +27.14% |
| Net income (latest FY) | $47.05M | $-51.06M |
| Gross margin | 54.59% | 69.32% |
| Operating margin | 7.46% | -18.48% |
| Net margin | 3.42% | -24.19% |
| 52-week high | $53.66 | $97.59 |
| 52-week low | $31.44 | $38.55 |
| Distance from 52-week high | -17.22% | -36.81% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +2.43% | +66.11% |
| Average volume | 466.28K | 427.57K |
| Shares outstanding | 29.95M | 29.80M |
| Employees | 3,900 | 1,004 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Industrial Specialties |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ESTA has outperformed CNMD by 55.9 percentage points over the past year.
- CONMED is more profitable, keeping 3.4 cents of every revenue dollar as net income versus -24.2 cents for Establishment Labs.
- Establishment Labs grew revenue faster in its latest fiscal year (+27.14% vs +5.18%).
About CONMED
CNMD stock →CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as powered resection instruments, fluid management and visualization systems, and related single-use products that enable surgeons to perform minimally invasive sports medicine surgeries.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 3,900 employees
About Establishment Labs
ESTA stock →Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for breast aesthetic and reconstructive plastic surgeries in Europe, the Middle East, Africa, Latin America, Asia, and the United States. The company offers silicone gel-filled breast implants under the Motiva Implants brand.
Health Care · Industrial Specialties · 1,004 employees
CNMD vs ESTA FAQ
Which is bigger, CONMED or Establishment Labs?
Establishment Labs (ESTA) is larger, with a market capitalization of $1.84B compared with $1.33B for CONMED (CNMD).
Which stock has performed better over the past year, CNMD or ESTA?
ESTA returned +53.71% over the past 12 months, compared with -2.18% for CNMD (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, CONMED or Establishment Labs?
CONMED pays a dividend yielding 0.45%, while Establishment Labs does not currently pay a regular dividend.
Are CONMED and Establishment Labs in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Electromedical & Electrotherapeutic Apparatus for CONMED and Industrial Specialties for Establishment Labs.